Article | May 13, 2026
Functional Tumor Biology Can’t Be Inferred. But It Can Be Measured.
Genomic sequencing has given us an extraordinary amount of information about tumors. We can now identify driver mutations, copy number alterations, and gene expression patterns faster and in a more cost-effective manner than ever before. But for all of that data, there is one question genomics still cannot answer: what is the tumor actually doing?
That answer lies in proteins, and more specifically, in the functional state of those proteins. Measuring functional tumor biology means measuring proteins directly, not inferring them from DNA or RNA data. This matters more than it might seem, because the gap between what the genome predicts and what proteins actually do is one of the most consistent reasons oncology drug programs fail.
Why Genomics Alone Leaves Critical Gaps
Genomics tells you which genes are mutated. Yet there are three layers of biology sitting between a genetic sequence and a functional outcome:
A mutated gene may or may not be transcribed into mRNA. Mutation does not equal expression.
Even when a gene is transcribed, mRNA levels do not reliably predict protein abundance. In cancer tissue, RNA-protein correlations are typically around 0.4, underscoring the difficulty to predict protein levels from mRNA.
Beyond expression, proteins are activated, inhibited, degraded, and relocated through modifications like phosphorylation and glycosylation. These dimensions are not captured in sequencing data.
In order for oncology drug development to de-risk such outcomes, we must be able to directly measure functional tumor biology rather than infer it.
What "Functional" Really Means in Tumor Proteomics
Functional tumor biology covers several distinct layers of protein activity. Each one shapes how a tumor behaves and, by extension, how it responds to treatment. These layers include:
Cell Surface Architecture
The proteins accessible at the tumor cell surface are the targets of ADCs, radioligand therapies, T-cell engagers, and immune checkpoint inhibitors. Measuring which of these proteins are actually surface-accessible on tumor versus normal tissue is what defines whether you have a viable therapeutic window. Gene expression data can suggest target candidates, but it cannot confirm surface accessibility.
Signaling Pathway Activity
A mutation does not tell you which signaling networks are actually activated in the tumor. Two tumors with the same KRAS mutation can have completely different downstream signaling profiles. Phosphoproteomics maps active kinase networks directly, showing which pathways are turned on regardless of what mutations started them.
Tumor Immune Microenvironment
Immune cell infiltration, checkpoint ligand expression, and immune evasion are driven by proteins. Sequencing gives you a rough picture, but cannot quantify these dynamics with the specificity needed for therapeutic decisions. That requires protein-level measurement.
Resistance Mechanisms
When a tumor develops resistance to treatment, the evidence is in the proteome. Drug efflux pumps, alternative survival pathways, and phenotypic plasticity are all protein-level phenomena. Because resistance mechanisms cannot be quantified via the genome, resistance has historically been treated as a retrospective explanation for therapeutic failure, recognized only after the tumor has adapted. With protein-level measurements, resistance becomes an actionable variable throughout the course of treatment.
From Protein Maps to Drug Development Decisions
Measuring functional tumor biology has practical value across drug development phases because it connects therapeutic hypotheses directly to what is happening in the tumor at the protein level. It moves decisions beyond genomic inference and into directly measured readouts of functional biology that reflect real target engagement and downstream effects.
- Target identification: Find targets that are functionally active at the protein level, not just mutated in the genome.
- Mechanism-of-action studies: Confirm a drug is hitting the right target and triggering the expected downstream signaling changes.
- Patient stratification: Identify protein-level biomarkers that separate responders from non-responders before or during a trial.
- Resistance profiling: Understand the protein changes that drive treatment resistance, which informs combination strategies and next-line options.
Mass Spectrometry as the Platform for Functional Tumor Biology
Modern mass spectrometry provides broad, quantitative protein coverage from a single tumor sample. With the right enrichment strategies for different protein classes, you can comprehensively probe the functional landscape of the tumor proteome.
Enter Sapient’s Tumor Protein Mapping Platform: a set of specialized proteomics workflows targeting distinct layer of functional tumor biology, including:
- SurfaceSeek™ to profile tumor cell surface proteins – specifically N-linked glycoproteins and membrane-anchored antigens – to not only map target accessibility but also evaluate target density, tumor selectivity, and therapeutic modality compatibility.
- SignalingSeek™ to map tumor signaling networks through phosphoproteomics, showing which kinase pathways are activated and how they connect.
- ImmuneSeek™ to quantify the tumor immune proteome, characterizing immune cell composition and checkpoint protein expression in the microenvironment.
- ResistanceSeek™ to characterize the protein-level adaptations that enable tumors to survive treatment pressure.
All of this proteomic data integrates with DynamiQ, Sapient’s AI-powered analysis engine, which translates protein-level measurements into findings you can act on.
Together, these approaches provide a comprehensive map of tumor protein biology – moving beyond genomic inference to direct measurement of the processes actively shaping disease.
From Educated Guesses to Functional Evidence
Active signaling states, immune microenvironment composition, accessible surface targets, resistance mechanisms: these are no longer things you have to predict. They can be measured directly, at scale, from clinical tumor samples including FFPE tissue.
Oncology R&D teams no longer need to rely on genomics alone to characterize tumor biology, and risk making decisions with a gap in knowledge of what lies between what is encoded in the genome and what is actually executed in the tumor. Functional tumor proteomics closes this gap, and we finally have the platforms to make these protein-level measurements effectively.
Summary of Key Questions Addressed
What is functional tumor biology?
Functional tumor biology refers to the active, protein-level processes in a tumor, including signaling pathway activity, surface protein expression, immune microenvironment composition, and resistance mechanisms. These functional states cannot be reliably captured from genomic or transcriptomic data.
Why can't functional tumor biology be captured by genomics?
Studies continue to show that mRNA levels and protein activity do not correlate reliably. Protein stability, localization, and activity are all regulated independently of the gene sequence. The only way to capture those states is to measure proteins directly.
What is tumor protein mapping?
Tumor protein mapping is the systematic, quantitative profiling of proteins in tumor samples, including surface proteins, signaling proteins, immune-related proteins, and resistance-associated proteins, using mass spectrometry-based proteomics.
What platforms can be used for functional tumor proteomics?
Sapient offers SurfaceSeek (cell surface proteomics), SignalingSeek (phosphoproteomics and signaling), ImmuneSeek (tumor immune proteome), and ResistanceSeek (resistance biology). Each is purpose-built for a specific functional layer of tumor biology.
What sample types are compatible with tumor protein mapping?
Sapient’s Tumor Protein Mapping Platform workflows are compatible with fresh-frozen tissue, FFPE tumor samples, cell lines, and patient-derived organoids, which means you can run both prospective studies and retrospective analyses using archived clinical material.